Globalization is a key context for the study of social determinants of health (SDH): broadly stated, SDH are the conditions in which people live and work, and that affect their opportunities to lead healthy lives. In the first article in this three part series, we described the origins of the series in work conducted for the Globalization Knowledge Network of the World Health Organizations Commission on Social Determinants of Health and in the Commissions specific concern with health equity.
Health equity in economic and trade policies
This second article of the series identifies and describes several, often interacting clusters of pathways leading from globalisation to changes in SDH that are relevant to health equity. These involve: trade liberalization; the global reorganization of production and labour markets; debt crises and economic restructuring; financial liberalization; urban settings; influences that operate by way of the physical environment; and health systems changed by the global marketplace.
Part 1 of this glossary introduced different health and trade arguments, overviewed the history of the World Trade Organisation (WTO), defined key "trade talk" terms, and reviewed three WTO treaties concerned with trade in goods (GATT 1994, the Agreement on Agriculture, and the Agreement on Sanitary and Phytosanitary Measures). Part 2 reviews five more agreements and the growing number of bilateral and regional trade agreements, and concludes with a commentary on different strategies proposed to ensure that health is not compromised by trade liberalisation treaties.
African governments are under intense pressure from within but also from big agribusiness and Western governments to embrace genetically modified organisms (GMOs). Throughout Africa, GMOs - organisms that have been biologically modified to incorporate genes with desired traits - are now being touted as a major solution to hunger and mass poverty. Supporters of biotechnology, like Kenyan-born Harvard scholar Prof Calestous Juma, believe that with GMOs Africa, which has 60 per cent of all the arable land, will be able to feed not just its people but the world. The author argues that governments must resist all forms of arm-twisting and food colonialism and make their biotechnology choices based on the facts. There are three basic concerns about GMOs. First, the science is at best inconclusive regarding the safety of genetically engineered organisms on human health and the environment. The second concern is about food sovereignty. Opponents are convinced that the campaign for GMOs is part of the neoliberal agenda to place agricultural production in the hands of a few corporate giants through seed patents and deny small farmers control of production. Finally, the author argues that the GMOs crusade distorts the debate about food security and poverty alleviation. The problems afflicting small farmers are argued to have very little to do with technology, and almost everything to do with unequal access to land, water, affordable inputs, markets and other resources.
The culture of secrecy that surrounds agricultural land deals raises concerns about government misconduct in relation to issues of public interest, according to this article. There is a growing global consensus in favour of contract transparency and a few governments have started publishing contracts or improving legislation on transparency, with Liberia leading the way. After a review and renegotiation of all extractive industry concessions and contracts, President Sirleaf introduced the Liberia Extractive Industry Transparency Initiative Act (the LEITI Act), which requires all payments by individual companies and operating contracts and licenses to be published and reviewed on the LEITI website. This bold step has not deterred investors, as initially feared. Other countries are following suit. Ghana has also started publishing contracts in the oil sector, and Ethiopia has started making certain contracts public, the article notes. Some countries, including Sierra Leone, Ghana and Liberia, require large investment projects to be ratified in parliament, ensuring a layer of public scrutiny.
The author argues that fair trade isn’t only about coffee and bananas. The Fairtrade Foundation points out that it doesn’t matter what the commodity is, people should get a fair price for the work they do. African gold miners are often exploited, but the author argues that workers do not have a choice; it’s dig or starve and it’s accept a pittance for their labors or work harder the following day. The Fairtrade Foundation is reported to have intervened and to be gradually improving conditions on mines. In this photo - essay Ian Berry reflects on the Ugandan gold trade as efforts are made to encourage fairer trading practices. He follows the gold from Ugandan mines to the London workshops of jewellers.
The struggle to make medicines affordable to the world’s poor, especially in Africa, is raging on at the highest levels. In the last week of October the European Commission took a landmark decision on generic drugs and next week a high-level intergovernmental meeting will look at ways to prevent patents from blocking access to drugs. In an agreement announced on October 23, European Union (EU) governments were told that they are free to make available generic versions of patented drugs for export to poor countries which lack their own manufacturing facilities.
Nearly a quarter of a million persons from more than 150 countries have voiced concerns over the negative impact that a legal challenge brought by the multinational pharmaceutical company Novartis against India's patent law could have on access to medicines in developing countries. The legal challenge brought by the Swiss-based Novartis against the government of India began to be heard in the Chennai High Court on Monday - despite an international petition launched by the international medical humanitarian organization Medicins Sans Frontieres (MSF) last December to put pressure on the company to drop its patent case against India.
Worldwide sales of counterfeit medicines could top US$75 billion this year, a 90% rise in five years, according to this article. The World Health Organization (WHO) is currently working with Interpol to dislodge the criminal networks making billions of dollars from the trade in counterfeit medicines and posing a growing threat to public health. In 2006, the International Medical Products Anti-Counterfeiting Task Force (IMPACT) was launched, drawing members from international organisations, enforcement agencies, industry and nongovernmental organisations. Sabine Kopp, IMPACT’s interim executive secretary and manager of WHO’s anti-counterfeiting programme, says that WHO is currently conducting a survey to compare legislation and terminology used to combat counterfeiting of medical products in different countries. It is difficult to measure the extent of the problem when there are so many sources of information and different definitions of 'counterfeit'.
Not long ago, the expansion of free trade worldwide seemed inevitable. Over the last few years, however, economic barriers have started to rise once more. The forecast for the future looks mixed: some integration will probably continue even as a new economic nationalism takes hold. Although globalisation as a process will continue to sputter along, the idea of unrestrained globalisation will wane in force. Managing this new, muddled world will take deft handling, in Washington, Brussels, and Beijing.
